L-Dihydroorotic acid

Names

[ Name ]:
L-Dihydroorotic acid

[Synonym ]:
(S)-dihydroorotic acid
dihydroorotate
MFCD00085339
(S)-2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid
(S)-2,6-dioxo-hexahydro-pyrimidine-4-carboxylic acid
4-Pyrimidinecarboxylic acid, 4,5-dihydro-2,6-dihydroxy-, (4S)-
(4S)-2,6-Dioxohexahydropyrimidine-4-carboxylic acid
(4S)-2,6-Dihydroxy-4,5-dihydro-4-pyrimidinecarboxylic acid
L-Dihydroorotic Acid
(4S)-2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid
EINECS 204-352-8
4-Pyrimidinecarboxylic acid, hexahydro-2,6-dioxo-, (4S)-

Biological Activity

[Description]:

L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme[1].

[Related Catalog]:

Research Areas >> Others

[Target]

Human Endogenous Metabolite

[References]

[1]. St. Louis, Missouri,et al. ENZYMATIC SYNTHESIS AND BREAKDOWN OF A PYRIMIDINE, OROTIC ACID.October 28, 1953.

Chemical & Physical Properties

[ Density]:
1.9±0.1 g/cm3

[ Boiling Point ]:
524.0±60.0 °C at 760 mmHg

[ Melting Point ]:
254-255 °C (dec.)(lit.)

[ Molecular Formula ]:
C₅H₆N₂O₄

[ Molecular Weight ]:
158.112

[ Flash Point ]:
270.7±32.9 °C

[ Exact Mass ]:
158.032761

[ PSA ]:
95.50000

[ LogP ]:
-2.29

[ Vapour Pressure ]:
0.0±3.1 mmHg at 25°C

[ Index of Refraction ]:
1.714

[ Storage condition ]:
Store at 0-5°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi:Irritant

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S26-S36

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ HS Code ]:
2934999001

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2934999001

Articles

SEC-TID: A Label-Free Method for Small-Molecule Target Identification.

J. Biomol. Screen. 19(6) , 917-927, (2014)

Bioactive small molecules are an invaluable source of therapeutics and chemical probes for exploring biological pathways. Yet, significant hurdles in drug discovery often come from lacking a comprehen...

The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites.

Biochemistry 47(34) , 8929-36, (2008)

Inhibitors of dihydroorotate dehydrogenase (DHODH) have been suggested for the treatment of rheumatoid arthritis, psoriasis, autoimmune diseases, Plasmodium, and bacterial and fungal infections. Here ...

Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH.

Hum. Mol. Genet. 21(18) , 3969-83, (2012)

Biallelic mutations in the gene encoding DHOdehase [dihydroorotate dehydrogenase (DHODH)], an enzyme required for de novo pyrimidine biosynthesis, have been identified as the cause of Miller (Genée-We...